Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health and its gastroenterology division, Salix Pharmaceuticals, have announced the opening of the 2022 Salix Gastrointestinal Health Scholars Program. This initiative will award scholarships of up to $10,000 to 10 students living with gastrointestinal diseases who are pursuing higher education. The application period runs until May 15, 2022, with recipient notifications expected in the summer. The program includes various awards categories, emphasizing the company’s commitment to supporting students.
KBRA has published its Fourth-Quarter 2021 U.S. Bank Compendium, offering insights into the U.S. banking sector's performance and credit metrics for the quarter. The report includes analyses of actions by larger banks regarding overdraft fees and features a quarterly ESG Bulletin. Notable highlights include summaries of publicly traded U.S. banks, key performance metrics, and data on top deposit franchises. Atlantic Union Bankshares Corporation (NASDAQ: AUB) is rated BBB+ with a positive outlook. For detailed insights, the full report is accessible online.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced its subsidiary, Solta Medical Corporation, has filed a registration statement for a proposed IPO of its common shares. The share price and offering size are yet to be determined. Solta aims to list on the Nasdaq under the symbol 'SLTA'. Bausch Health has completed internal steps for launching both Solta and Bausch + Lomb IPOs, pending regulatory approvals. Major investment firms, including Goldman Sachs and Morgan Stanley, are managing the offering.
Bausch Health Companies (NYSE/TSX: BHC) will announce its financial results for Q4 and full-year 2021 on February 23, 2022. A conference call is scheduled for 8:00 a.m. ET to discuss the results and provide a business update. Investors can access the call through the company’s Investor Relations website. Bausch Health focuses on improving lives through its health care products, primarily in eye health, gastroenterology, and dermatology.
Bausch + Lomb partners with Prevent Blindness for the seventh year during AMD Awareness Month, launching a campaign aimed at educating the public on Age-Related Macular Degeneration (AMD), which affects 16 million adults in the U.S. The initiative aims to raise awareness and funds, contributing $1 for each social media interaction, with a goal of $50,000. Bausch + Lomb's president emphasized the importance of eye examinations, as early diagnosis is crucial. The company also plans to release its Visionary Report to identify AMD education gaps.
Bausch Health Companies (BHC) has priced an offering of $1.0 billion in 6.125% senior secured notes due 2027. The proceeds will be utilized for refinancing efforts, encompassing existing loans and the redemption of senior notes due 2025. The refinancing will involve $2.5 billion in term loans and a $975 million revolving credit facility, contingent on the completion of the Bausch + Lomb IPO. The Notes are secured by existing assets and are offered under specific exemptions from registration laws.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has launched a $1.0 billion offering of new senior secured notes due 2027. The company also plans to refinance its existing credit agreement, which includes approximately $2.5 billion in new term B loans and a $975 million revolving credit facility. Proceeds will fund the redemption of outstanding 6.125% and 9.000% senior notes due 2025 and related expenses. The redemption is conditional upon completing the refinancing and receiving at least $7.0 billion from related transactions. The offering is not registered under U.S. securities laws.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that Dr. Yehia Hashad will join Bausch + Lomb as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective January 31, 2022. Dr. Hashad brings over 25 years of experience in the pharmaceutical industry, with significant expertise in ophthalmic pharmaceuticals from Allergan/AbbVie and Novartis. His appointment aims to enhance the R&D capabilities at Bausch + Lomb, a leader in eye health products and services, as the company continues to innovate and build on its 170-year legacy.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to refinance its existing credit agreement, involving $2.5 billion in Term B loans and a $975 million revolving credit facility. The refinancing is contingent upon the initial public offering (IPO) of Bausch + Lomb, expected to enable Bausch Health to designate Bausch + Lomb as an unrestricted subsidiary. Additionally, the company plans to issue $1 billion in secured debt securities to facilitate the redemption of existing notes. The transactions are subject to market conditions and are expected to close in Q1 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a significant step towards separating its eye health business by filing a Registration Statement on Form S-1 for a proposed IPO of its subsidiary, Bausch + Lomb. The IPO aims to sell common shares in both the U.S. and Canada, with specifics on share quantity and pricing yet to be determined. Major financial institutions like Morgan Stanley and Goldman Sachs are leading the offering, with market conditions influencing the timing and structure of the transaction. There are no assurances regarding the IPO's completion.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
